

DAFTAR REFERENSI

- Badan Pengawas Obat dan Makanan. (2020). *Modul Farmakovigilans Dasar*.
- BPOM. (2020). *Informatorium Obat Covid-19 di Indonesia* (B. P. O. & M. R. Indonesia (ed.); Pertama). Badan Pengawas Obat & Makanan Republik Indonesia. online.flipbuilder.com/tbog/infi/mobile/index.html
- Chouchana, L., Boujaafar, S., Gana, I., Preta, L. H., Regard, L., Legendre, P., Azoulay, C., Canoui, E., Zerbit, J., Carlier, N., Terrier, B., Kernéis, S., Batista, R., Treluyer, J. M., Zheng, Y., & Benaboud, S. (2021). Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients. *Therapeutic Drug Monitoring*, 43(1), 131–135. <https://doi.org/10.1097/FTD.0000000000000838>
- Crescioli, G., Brilli, V., Lanzi, C., Burgalassi, A., Ieri, A., Bonaiuti, R., Romano, E., Innocenti, R., Mannaioni, G., Vannacci, A., & Lombardi, N. (2020). Adverse Drug Reactions In SARS Cov 2 Hospitalised Patients: A Case Series With A Focus On Drug–Drug Interactions. *Internal and Emergency Medicine*. <https://doi.org/https://doi.org/10.1007/s11739-020-02586-8>
- Falcão, F., Viegas, E., Carmo, I., Soares, J., Falcao, M., Solano, M., Cavaco, P., Mendes, D., Rijo, J., Povoa, P., Pais Martins, A., Carmo, E., Mansinho, K., Fonseca, C., Campos, L., Carvalho, A., Mirco, A., Farinha, H., Aldir, I., & Correia, J. (2021). A Prospective, Observational Study to Evaluate Adverse Drug Reactions in Patients With COVID-19 Treated with Remdesivir or Hydroxychloroquine: A Preliminary Report. *European Journal of Hospital Pharmacy*, 1–6. <https://doi.org/10.1136/ejhp pharm-2020-002613>
- Fresse, A., Viard, D., Romani, S., Gérard, A., Lepelley, M., Rocher, F., Salem, J. E., & Drici, M. D. (2021). Spontaneous Reported Cardiotoxicity Induced By Lopinavir/Ritonavir in COVID-19. An Alleged Past-Resolved Problem. *International Journal of Cardiology*, 324(xxxx), 255–260. <https://doi.org/10.1016/j.ijcard.2020.10.028>
- Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (2019). Cochrane handbook for systematic reviews of interventions. *Cochrane Handbook for Systematic Reviews of Interventions*,

- 1–694. <https://doi.org/10.1002/9781119536604>
- Inoue, H., Jinno, M., Ohta, S., Kishino, Y., Kawahara, T., Mikuni, H., Sato, H., Yamamoyo, M., Sato, Y., Onitsuka, C., Goto, Y., Ikeda, H., Sato, H., Uno, T., Uchida, Y., Kimura, T., Miyata, Y., Hirai, K., Homma, T., ... Sagara, H. (2020). Combination Treatment of Short-Course Systemic Corticosteroid and Favipiravir in a Successfully Treated Case of Critically ill COVID-19 Pneumonia with COPD. *Respiratory Medicine Case Report*, 31(August), 2213–0071. <https://doi.org/https://doi.org/10.1016/j.rmcr.2020.101200>
- Jiang, Y., Yin, W., & Xu, H. E. (2020). RNA-Dependent RNA Polymerase: Structure, Mechanism, and Drug Discovery for COVID-19. *Biochemical and Biophysical Research Communications*, xxxx. <https://doi.org/10.1016/j.bbrc.2020.08.116>
- Kemenkes RI. (2020). Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). In L. Aziza, A. Aqmarina, & M. Ihsan (Eds.), *GERMAS* (4th ed.). Kementerian Kesehatan Republik Indonesia, Direktorat Jendral Pencegahan dan Pengendalian Penyakit (P2P). <http://infeksiemerging.kemkes.go.id>
- Kitchenham, B. (2004). Procedures for Performing Systematic Reviews. In K. U. T. R. TR (Ed.), *Department of Computer Science* (Issue 1). Keele University Technical.
- Lai, C. K. C., & Lam, W. (2020). Laboratory Testing For The Diagnosis of COVID-19. *Biochemical and Biophysical Research Communications*, xxxx. <https://doi.org/10.1016/j.bbrc.2020.10.069>
- Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. In *Journal of clinical epidemiology* (Vol. 62, Issue 10). <https://doi.org/10.1016/j.jclinepi.2009.06.006>
- Meilani, D., & Sinuraya, R. K. (2018). Pharmacovigilance Dalam Aspek Penanganan Reaksi Obat Yang Tidak Diinginkan: Sebuah Artikel Review. *Farmaka*, 16(Vol 16, No 1 (2018): Farmaka (Juni)), 103–112.

- <http://jurnal.unpad.ac.id/farmaka/article/view/17037>
- Moola, S., Munn, Z., Tufanaru, C., Aromataris, E., Sears, K., Sfetcu, R., Currie, M., Qureshi, R., Mattis, P., Lisy, K., & Mu, P.-F. (2017). Checklist for Cohort Studies. *Joanna Briggs Institute Reviewer's Manual*, 1–7. https://joannabriggs.org/ebp/critical_appraisal_tools
- Nofiarny, D. (2016). Pengenalan Farmakovigilans : Apa dan Mengapa Diperlukan ? *Medicinus*, 29(April), 53–56.
- Pariang, N. F. . (2020). Panduan Praktis Untuk Apoteker. *Pengurus Pusat Ikatan Apoteker Indonesia*, 53(9), 1779–1791.
- Parvathaneni, V., & Gupta, V. (2020). Utilizing Drug Repurposing Against COVID-19 – Efficacy, Limitations, and Challenges. *Life Sciences*, 259(July), 118275. <https://doi.org/10.1016/j.lfs.2020.118275>
- Rajaiah, R., Abhilasha, K. V., Shekar, M. A., Vogel, S. N., & Vishwanath, B. S. (2020). Evaluation of Mechanisms of Action of Re-Purposed Drugs for Treatment of COVID-19. *Cellular Immunology*, 358(September), 104240. <https://doi.org/10.1016/j.cellimm.2020.104240>
- Rusli. (2018). *Farmasi Klinik* (1st ed.). Kementrian Kesehatan Republik Indonesia.
- Siswanto, S. (2012). Systematic Review Sebagai Metode Penelitian Untuk Mensintesis Hasil-Hasil Penelitian (Sebuah Pengantar). *Buletin Penelitian Sistem Kesehatan*, 13(4), e1–e34. <https://doi.org/10.22435/bpsk.v13i4>
- Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Herikurniawan, H., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E. J., Chen, L. K., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C. O. M., & Yunihastuti, E. (2020). Coronavirus Disease 2019: Tinjauan Literatur Terkini. *Jurnal Penyakit Dalam Indonesia*, 7(1), 45. <https://doi.org/10.7454/jpdi.v7i1.415>
- Udugama, B., Kadhiresan, P., Kozlowski, H. N., Malekjahani, A., Osborne, M., Li, V. Y. C., Chen, H., Mubareka, S., Gubbay, J. B., & Chan, W. C. W. (2020). Diagnosing COVID-19: The Disease and Tools for Detection. *ACS Nano*, 14(4), 3822–3835. <https://doi.org/10.1021/acsnano.0c02624>
- Vlachakis, D., Papakonstantinou, E., Mitsis, T., Pierouli, K., Diakou, I., Chrouzos, G., & Bacopoulou, F. (2020). Molecular Mechanisms of the Novel

- Coronavirus SARS-CoV-2 and Potential Anti-COVID19 Pharmacological Targets Since the Outbreak of the Pandemic. *Food and Chemical Toxicology*, 146(October), 111805. <https://doi.org/10.1016/j.fct.2020.111805>
- WHO. (2020). Covid-19 Strategy Up Date. *Covid-19 Strategy Update*, 3(April), 18. WWW.who.int/emergencies/en
- Ye, Q., Wang, B., & Mao, J. (2020). The Pathogenesis and Treatment of the ‘Cytokine Storm’ in COVID-19. *Journal of Infection*, 8D(January), 607–613. <https://doi.org/https://doi.org/10.1016/j.jinf.2020.03.037>
- Yofrido, F. M., Christine, I., & Harjana, L. T. (2018). Pemanjangan Interval Qt Terkoreksi (Qtc) Pada Pasien Hipokalemia Berat Dengan Penyulit Aritmia Ventrikel Fatal. *Jurnal Widya Medika*, 4(2), 106–113.
- Yuan, J., Li, M., Yu, T. L., Lv, B., Han, B., Xiang, X., & Lu, Z. K. (2021). Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS). *Original Research Article Pharmacotherapy*. <https://doi.org/https://doi.org/10.1007/s40801-021-00229-8>
- Zhao, H., Zhu, Q., Zhang, C., Li, J., Wei, M., Qin, Y., & Chen, G. (2020). Tocilizumab Combined With Favipiravir In The Treatment of COVID-19: A Multicenter Trial in a Small Sample Size. *Biomedicine & Pharmacotherapy*, 133(110825), 1–7.